Indraprastha Medical Corporation Ltd

Indraprastha Medical Corporation Ltd (IMCL), a small-cap player in the hospital sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a modest day change of -0.09% and a challenging year-to-date return of -15.05%, the company’s valuation metrics now present a compelling case for investors seeking value in a sector dominated by expensive peers.

Indraprastha Medical Corporation Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Indraprastha Medical Corporation Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a recent downgrade in its overall Mojo Grade to Sell. This article analyses the evolving price attractiveness of the hospital sector stock, comparing its key valuation metrics against historical averages and peer benchmarks to provide a comprehensive view for investors.

Indraprastha Medical Corporation Ltd, a small-cap player in the hospital sector, has experienced a notable shift in its technical momentum, reflected in a recent upgrade from Hold to Sell by MarketsMOJO. Despite a strong intraday price surge of 6.80% to ₹402.15, the stock’s technical indicators present a complex picture, with a transition from bearish to mildly bearish trends and mixed signals across key metrics such as MACD, RSI, and moving averages.

Indraprastha Medical Corporation Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions and improved price metrics relative to its historical averages and peer group, signalling a potentially favourable entry point for investors amid a challenging hospital sector landscape.

The Sensex declined 0.3% on 03 Jun 2026, while Indraprastha Medical Corporation Ltd surged 7.13%, marking a notable 5.8-percentage-point outperformance over its Hospital sector peers. This sharp intraday advance rewrites the short-term narrative for the stock, which has been steadily gaining over the past two sessions.

Indraprastha Medical Corporation Ltd is rated Sell by MarketsMOJO. This rating was last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Indraprastha Medical Corporation Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating. This change reflects a more favourable price-to-earnings (P/E) and price-to-book value (P/BV) ratio compared to its historical averages and peer group, despite ongoing sector headwinds and a modest downgrade in its overall mojo grade to Sell.

Indraprastha Medical Corporation Ltd, a small-cap player in the hospital sector, has seen a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. Despite a modest intraday gain of 1.93% to close at ₹371.65, the stock’s broader technical indicators signal caution for investors amid weakening momentum and mixed signals across key oscillators and moving averages.

Indraprastha Medical Corporation Ltd, a small-cap player in the hospital sector, has experienced a nuanced shift in its technical landscape, reflecting a complex interplay of momentum indicators and moving averages. Despite a modest daily gain of 1.52%, the stock’s broader technical parameters suggest a cautious outlook, with several bearish signals tempered by mild bullish undertones.

Indraprastha Medical Corporation Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Indraprastha Medical Corporation Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Indraprastha Medical Corporation Ltd, a small-cap player in the hospital sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This transition is underscored by a series of technical indicators signalling weakening price momentum, with the stock currently trading at ₹360.05, down 2.15% from its previous close of ₹367.95.

Indraprastha Medical Corporation Ltd., the Delhi-based hospital chain operating the flagship Indraprastha Apollo Hospital, reported net profit of ₹41.70 crores for Q4 FY26 (Mar'26), marking a modest sequential growth of 1.71% from ₹41.00 crores in Q3 FY26 (Dec'25), whilst delivering a solid 1.68% year-on-year improvement over ₹41.01 crores in Q4 FY25. With a market capitalisation of ₹3,682 crores, the small-cap hospital operator faces mounting concerns over margin compression and operational efficiency despite maintaining revenue momentum.

Indraprastha Medical Corporation Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Indraprastha Medical Corporation Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.